MCID: LYM118
MIFTS: 69

Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Lymphoma

MalaCards integrated aliases for Lymphoma:

Name: Lymphoma 12 74 58 29 54 6 42 43 15 17 71
Lymphoid Neoplasm 71
Lymphoid Cancers 71
Lymphoid Cancer 12
Lymphomas 15

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0060058
MeSH 43 D008223
NCIt 49 C3208 C7065
SNOMED-CT 67 21964009
ICD10 32 C85.9
MESH via Orphanet 44 D008223
UMLS via Orphanet 72 C0024299
Orphanet 58 ORPHA223735
UMLS 71 C0024299 C0598798 C0746336

Summaries for Lymphoma

MedlinePlus : 42 Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss Fever Soaking night sweats Coughing, trouble breathing or chest pain Weakness and tiredness that don't go away Pain, swelling or a feeling of fullness in the abdomen Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute

MalaCards based summary : Lymphoma, also known as lymphoid neoplasm, is related to lymphoma, non-hodgkin, familial and lymphoma, mucosa-associated lymphoid type. An important gene associated with Lymphoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are IL-2 Pathway and PI3K-Akt signaling pathway. The drugs Ferrous succinate and Tropisetron have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.

Wikipedia : 74 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for Lymphoma

Diseases in the Lymphoma family:

Adult Lymphoma Eye Lymphoma

Diseases related to Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2874)
# Related Disease Score Top Affiliating Genes
1 lymphoma, non-hodgkin, familial 36.1 TP53 TCL1A MYC MALT1 CXCR5 CCND1
2 lymphoma, mucosa-associated lymphoid type 36.0 TP53 MYC MALT1 CXCR5 CCND1 BCL6
3 follicular lymphoma 35.9 MYC CXCR5 CCND1 BCL6 BCL2 BCL10
4 burkitt lymphoma 35.9 TP53 TCL1A PVT1 PMS2 MYC CXCR5
5 diffuse large b-cell lymphoma 35.9 TP53 TCL1A MYC MALT1 CCND1 BCL6
6 peripheral t-cell lymphoma 35.7 TP53 TCL1A CCND1 BCL6 ATM ALK
7 lymphoma, hodgkin, classic 35.7 PVT1 BCL6 BCL2 ALK
8 primary central nervous system lymphoma 35.6 CXCR5 BCL6 BCL2
9 gastric lymphoma 35.5 TP53 MALT1 CXCR5 BCL6 BCL10
10 intraocular lymphoma 35.5 CXCR5 BCL6 BCL2
11 lymphoma aids related 35.4 TCL1A MYC BCL6
12 marginal zone b-cell lymphoma 35.4 MALT1 CCND1 BCL6 BCL2 BCL10
13 follicular lymphoma 1 35.3 BCL6 BCL2 BCL10
14 central nervous system lymphoma 35.3 TP53 MYC MALT1 CXCR5 BCL6
15 b-cell lymphoma 35.3 TP53 TCL1A PVT1 MYC MALT1 GAS5
16 lymphoblastic lymphoma 35.2 TP53 MYC BCL6
17 mantle cell lymphoma 35.2 TP53 TCL1A MYC MALT1 GAS5 CCND1
18 primary mediastinal b-cell lymphoma 35.2 TCL1A BCL6 BCL2
19 nodular lymphocyte predominant hodgkin lymphoma 35.1 CCND1 BCL6
20 alk-negative anaplastic large cell lymphoma 35.1 MYC BCL2 BAX ALK
21 plasmablastic lymphoma 35.0 MYC BCL6
22 nodal marginal zone b-cell lymphoma 34.9 MALT1 BCL6 BCL2
23 primary mediastinal large b-cell lymphoma 34.8 BCL6 BCL2
24 b-cell non-hodgkin lymphoma 34.8 BCL7A BCL6 ATM
25 pediatric lymphoma 34.8 TCL1A MYC BCL6 ALK
26 primary cutaneous marginal zone b-cell lymphoma 34.8 MALT1 BCL10
27 gastrointestinal lymphoma 34.7 MALT1 CCND1 BCL6
28 reticulosarcoma 34.7 MYC BCL6 BCL2 ALK
29 adult lymphoma 34.7 MYC BCL6 ALK
30 acute t cell leukemia 34.7 TP53 TCL6 MYC BCL10 BAX
31 diffuse large b-cell lymphoma of the central nervous system 34.7 MYC BCL2
32 eye lymphoma 34.7 CXCR5 BCL6
33 intravascular large b-cell lymphoma 34.7 BCL6 BCL2
34 orbit lymphoma 34.7 MALT1 BCL10
35 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 34.7 CXCR5 BCL6
36 lung lymphoma 34.6 MALT1 BCL6
37 breast lymphoma 34.6 BCL6 ALK
38 heart lymphoma 34.6 BCL6 ALK
39 leukemia, acute lymphoblastic 34.4 PTPN11 PMS2 BCL6 BCL2 BAX ATM
40 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 34.4 MYC BCL6 BCL2
41 precursor t-cell acute lymphoblastic leukemia 33.9 TCL1A MYC BCL10 BAX
42 richter's syndrome 33.9 TP53 MYC ATM
43 cll/sll 33.8 TP53 CCND1 BCL6 ATM
44 leukemia, chronic lymphocytic 33.7 TP53 TCL1A PTPN11 MYC DLEU2 CXCR5
45 gastric adenocarcinoma 33.6 TP53 MYC CCND1 BCL2 BAX ATM
46 monoclonal gammopathy of uncertain significance 33.4 TP53 MYC CCND1
47 human herpesvirus 8 33.0 BCL6 BCL2
48 acquired immunodeficiency syndrome 32.8 TP53 MYC CXCR5 CCND1 BCL6
49 lymphocytic leukemia 32.6 TP53 PTPN11 MYC DLEU2 CCND1 BCL2
50 adenocarcinoma 32.5 TP53 MYC CCND1 BCL2 BAX ALK

Graphical network of the top 20 diseases related to Lymphoma:



Diseases related to Lymphoma

Symptoms & Phenotypes for Lymphoma

GenomeRNAi Phenotypes related to Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 ATM BAX BCL10 BCL2 MALT1 TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 ATM BAX BCL10 BCL2 CCND1 MALT1

MGI Mouse Phenotypes related to Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 ATM BAX BCL10 BCL2 BCL6 CCND1
2 hematopoietic system MP:0005397 10.15 ATM BAX BCL10 BCL2 BCL6 CCND1
3 endocrine/exocrine gland MP:0005379 10.14 ALK ATM BAX BCL10 BCL2 BCL6
4 immune system MP:0005387 10.1 ATM BAX BCL10 BCL2 BCL6 CCND1
5 mortality/aging MP:0010768 10.07 ALK ATM BAX BCL10 BCL2 BCL6
6 neoplasm MP:0002006 9.81 ALK ATM BAX BCL2 CCND1 MYC
7 reproductive system MP:0005389 9.36 ALK ATM BAX BCL2 BCL6 CCND1
8 pigmentation MP:0001186 9.35 ALK BCL2 MYC PTPN11 TP53

Drugs & Therapeutics for Lymphoma

Drugs for Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 900)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ferrous succinate Approved Phase 4 10030-90-7
2
Tropisetron Approved, Investigational Phase 4 89565-68-4, 105826-92-4 5595
3
Palonosetron Approved, Investigational Phase 4 119904-90-4, 135729-61-2, 135729-56-5 148211
4
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
5
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
6
Nitric Oxide Approved Phase 4 10102-43-9 145068
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
9
Adalimumab Approved Phase 4 331731-18-1 16219006
10
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
11
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
12
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
13
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
14
Protein C Approved Phase 4
15
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
16
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
17
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
18
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
19
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
20
Potassium citrate Approved, Investigational, Vet_approved Phase 4
21
Lithium carbonate Approved Phase 4 554-13-2
22
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
23
Morphine Approved, Investigational Phase 4 57-27-2 5288826
24
Epirubicin Approved Phase 4 56420-45-2 41867
25
Nicotine Approved Phase 4 54-11-5 942 89594
26
Infliximab Approved Phase 4 170277-31-3
27
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
28
Prilocaine Approved Phase 4 721-50-6 4906
29
Teniposide Approved Phase 4 29767-20-2 34698
30
Ofloxacin Approved Phase 4 82419-36-1 4583
31
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
32
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
33
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
34
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
35
Clarithromycin Approved Phase 4 81103-11-9 84029
36
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
37
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
38
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
39
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
40
Glucagon Approved Phase 4 16941-32-5
41
Liraglutide Approved Phase 4 204656-20-2 44147092
42
Zidovudine Approved Phase 4 30516-87-1 35370
43
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
44
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
45
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
46
Ribavirin Approved Phase 4 36791-04-5 37542
47
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
48
Methoxsalen Approved Phase 4 298-81-7 4114
49
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
50
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2

Interventional clinical trials:

(show top 50) (show all 7225)
# Name Status NCT ID Phase Drugs
1 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Unknown status NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
2 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
3 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
4 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
5 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
6 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
7 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
8 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
9 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
10 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
11 A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
12 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
13 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
14 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
15 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
16 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
17 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
18 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
19 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
20 A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02576327 Phase 4 Tropisetron;Dexamethasone;Aprepitant
21 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
22 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
23 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
24 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
25 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
26 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
27 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
28 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
29 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
30 A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines Unknown status NCT01841671 Phase 4
31 Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study Completed NCT01569724 Phase 4
32 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
33 The Multi-center,Open-label,Single Arm Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
34 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
35 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
36 AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4 Aprepitant;Palonosetron;Granisetron
37 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
38 A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens Completed NCT00090038 Phase 4 rituximab
39 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
40 A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
41 Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
42 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
43 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
44 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
45 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
46 A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide ) Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
47 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
48 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
49 A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
50 Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)

Search NIH Clinical Center for Lymphoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ASPARAGINASE
Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Cochrane evidence based reviews: lymphoma

Genetic Tests for Lymphoma

Genetic tests related to Lymphoma:

# Genetic test Affiliating Genes
1 Lymphoma 29

Anatomical Context for Lymphoma

MalaCards organs/tissues related to Lymphoma:

40
B Cells, T Cells, Bone, Bone Marrow, Lung, Breast, Thyroid

Publications for Lymphoma

Articles related to Lymphoma:

(show top 50) (show all 58107)
# Title Authors PMID Year
1
The Role of Metoprolol and Enalapril in the Prevention of Doxorubicin-induced Cardiotoxicity in Lymphoma Patients. 42 61
31570470 2019
2
Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis. 42
31626107 2019
3
Cluster of differentiation 30 expression in lacrimal gland and conjunctival tissues in patients with Sjögren's syndrome: Case series. 42
31335688 2019
4
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. 61 54
20299510 2010
5
Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. 54 61
20484818 2010
6
Notch1 in primary effusion lymphoma: a clinicopathological study. 61 54
20348880 2010
7
Common misdiagnoses in lymphomas and avoidance strategies. 61 54
20227918 2010
8
Oncogenic activation of NF-kappaB. 54 61
20516126 2010
9
C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. 54 61
20015877 2010
10
Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. 54 61
19948376 2010
11
Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. 54 61
20207982 2010
12
Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice. 54 61
20124219 2010
13
Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis. 61 54
20179179 2010
14
Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. 54 61
20406193 2010
15
An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. 54 61
20490333 2010
16
Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review. 54 61
19774614 2010
17
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. 54 61
20062012 2010
18
BCL6, MUM1, and CD10 expression in mantle cell lymphoma. 54 61
19826251 2010
19
C-C chemokine receptor 1 expression in human hematolymphoid neoplasia. 54 61
20154287 2010
20
Determining the expression rate of the IgM and IgA in B cell lymphomas by immunohistochemistry. 61 54
20437688 2010
21
PD-1 expression in T-cell lymphomas and reactive lymphoid entities: potential overlap in staining patterns between lymphoma and viral lymphadenitis. 61 54
20087161 2010
22
Sodium valproate in combination with ganciclovir induces lysis of EBV-infected lymphoma cells without impairing EBV-specific T-cell immunity. 61 54
19196381 2010
23
CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. 61 54
20004001 2010
24
[Expression and function of TRAF1 in Hodgkin's lymphoma cells.]. 54 61
20302775 2010
25
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 61 54
20054396 2010
26
Lymphoma cells contribute to the augmentation of plasma sL-selectins in the serum of lymphoma-bearing mice. 61 54
20001233 2010
27
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 61 54
20023257 2010
28
Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. 54 61
19963099 2009
29
Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. 54 61
19625084 2009
30
To the genesis of Burkitt lymphoma: regulation of apoptosis by EBNA-1 and SAP may determine the fate of Ig-myc translocation carrying B lymphocytes. 61 54
19874894 2009
31
Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome. 61 54
19816150 2009
32
Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth. 54 61
20043832 2009
33
Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas. 61 54
19716163 2009
34
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. 61 54
19966776 2009
35
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? 61 54
19358142 2009
36
Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells. 54 61
19725825 2009
37
[Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma]. 54 61
20079013 2009
38
Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. 54 61
19880779 2009
39
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. 61 54
19880778 2009
40
CD44 expression during tumor progression of follicular lymphoma. 54 61
19787231 2009
41
Diffuse blastoid B-cell lymphoma: a histologically aggressive variant of t(14;18)-negative follicular lymphoma. 61 54
19633642 2009
42
Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis. 61 54
19907659 2009
43
Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. 61 54
19608671 2009
44
The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. 54 61
19551857 2009
45
AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. 61 54
19941823 2009
46
Speckled-like pattern in the germinal center (SLIP-GC), a nuclear GTPase expressed in activation-induced deaminase-expressing lymphomas and germinal center B cells. 61 54
19734146 2009
47
Identification of MNDA as a new marker for nodal marginal zone lymphoma. 54 61
19474799 2009
48
Functional signatures identified in B-cell non-Hodgkin lymphoma profiles. 61 54
19863341 2009
49
P38 mitogen activated protein kinase expression and regulation by interleukin-4 in human B cell non-Hodgkin lymphomas. 54 61
20309428 2009
50
Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis. 54 61
19525926 2009

Variations for Lymphoma

ClinVar genetic disease variations for Lymphoma:

6 (show all 15) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PTPN11 NM_002834.4(PTPN11):c.188A>G (p.Tyr63Cys)SNV Pathogenic 13333 rs121918459 12:112888172-112888172 12:112450368-112450368
2 PMS2 NM_000535.7(PMS2):c.1831dup (p.Ile611fs)duplication Pathogenic 91317 rs63750250 7:6026565-6026565 7:5986934-5986934
3 PMS2 NM_000535.7(PMS2):c.736_741delinsTGTGTGTGAAG (p.Pro246_Pro247delinsCysValTer)indel Pathogenic 91366 rs267608150 7:6037019-6037024 7:5997388-5997393
4 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic/Likely pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
5 KMT2D NM_003482.3(KMT2D):c.11897_11911del (p.Phe3966_Gln3971delinsTer)deletion Likely pathogenic 638280 12:49426577-49426591 12:49032794-49032808
6 KMT2D NM_003482.3(KMT2D):c.10622_10623CT[1] (p.Leu3542fs)short repeat Likely pathogenic 638279 12:49427965-49427966 12:49034182-49034183
7 SETBP1 NM_015559.3(SETBP1):c.1703G>T (p.Ser568Ile)SNV Likely pathogenic 638281 18:42531008-42531008 18:44951043-44951043
8 EZH2 NM_004456.4(EZH2):c.1936T>A (p.Tyr646Asn)SNV Likely pathogenic 376217 rs267601395 7:148508728-148508728 7:148811636-148811636
9 EZH2 NM_004456.4(EZH2):c.1937A>C (p.Tyr646Ser)SNV Likely pathogenic 376218 rs267601394 7:148508727-148508727 7:148811635-148811635
10 EZH2 NM_004456.4(EZH2):c.2045C>G (p.Ala682Gly)SNV Likely pathogenic 376219 rs1057519833 7:148506467-148506467 7:148809375-148809375
11 EZH2 NM_004456.4(EZH2):c.1937A>T (p.Tyr646Phe)SNV Likely pathogenic 76768 rs267601394 7:148508727-148508727 7:148811635-148811635
12 EZH2 NM_004456.4(EZH2):c.1936T>C (p.Tyr646His)SNV Likely pathogenic 76769 rs267601395 7:148508728-148508728 7:148811636-148811636
13 MYD88 NM_001172567.2(MYD88):c.779T>C (p.Leu260Pro)SNV Uncertain significance 37055 rs387907272 3:38182641-38182641 3:38141150-38141150
14 NSD2 NM_001042424.3(NSD2):c.3295G>A (p.Glu1099Lys)SNV Uncertain significance 638278 4:1962801-1962801 4:1961074-1961074
15 IDH1 NM_005896.3(IDH1):c.784G>A (p.Glu262Lys)SNV Uncertain significance 638277 2:209106784-209106784 2:208242060-208242060

Copy number variations for Lymphoma from CNVD:

7 (show all 24)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 22797 1 168900 170100 Copy number Lymphoma
2 23565 1 171600 171900 Copy number Lymphoma
3 23675 1 172800 176700 Copy number Lymphoma
4 25326 1 187500 188100 Copy number Lymphoma
5 82146 14 105300 105900 Copy number Lymphoma
6 83536 14 21300 22200 Copy number Lymphoma
7 159014 21 39019555 39028514 Amplification KCNJ6 Lymphoma
8 159212 21 41403021 41411848 Amplification DSCAM Lymphoma
9 159621 21 43701285 43716936 Amplification ABCG1 Lymphoma
10 159656 21 43999157 44011961 Amplification SLC37A1 Lymphoma
11 159668 21 44081762 44094899 Amplification PDE9A Lymphoma
12 159699 21 44433424 44441413 Amplification PKNOX1 Lymphoma
13 159719 21 44574984 44589646 Amplification Lymphoma
14 159916 21 45919335 45928378 Amplification C21orf29 Lymphoma
15 159943 21 46246130 46270192 Amplification PTTG1IP Lymphoma
16 162160 22 21300 21600 Copy number Lymphoma
17 205715 6 13200 17100 Copy number Lymphoma
18 208659 6 1800 4200 Copy number Lymphoma
19 208796 6 19800 23100 Copy number Lymphoma
20 213994 6 5400 6300 Copy number Lymphoma
21 220996 7 141900 142200 Copy number Lymphoma
22 224818 7 38100 38700 Copy number Lymphoma
23 233910 8 128816946 128822855 Amplification MYC Lymphoma
24 149232 2 88800 89400 Copy number Lymphoma

Expression for Lymphoma

Search GEO for disease gene expression data for Lymphoma.

Pathways for Lymphoma

Pathways related to Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.23 TP53 MYC MALT1 CCND1 BCL2 BCL10
2
Show member pathways
12.97 TP53 TCL1A MYC CCND1 BCL2 BAX
3
Show member pathways
12.95 TP53 MYC CCND1 BCL2 BAX ATM
4
Show member pathways
12.89 TP53 PTPN11 MYC CCND1 BCL2 BAX
5 12.86 TP53 MYC CCND1 BCL2 BAX ALK
6
Show member pathways
12.83 TP53 MYC CCND1 BCL2 BAX
7
Show member pathways
12.82 TP53 MYC BCL2 BAX ATM
8
Show member pathways
12.77 TP53 MYC CCND1 BCL2 BAX
9
Show member pathways
12.71 TP53 MYC CCND1 BCL2 BAX ATM
10
Show member pathways
12.66 TP53 CCND1 BCL2 BAX ATM ALK
11
Show member pathways
12.6 TP53 PTPN11 MYC BCL2 BAX
12
Show member pathways
12.58 TP53 PTPN11 MYC CCND1 BCL2 BAX
13 12.56 TP53 MYC CCND1 BCL2 ATM
14
Show member pathways
12.5 PTPN11 MYC CCND1 BCL2 BAX
15
Show member pathways
12.45 TP53 BCL2 BAX ATM
16